IkappaB kinase beta inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIkappaB kinase beta inhibitors (Boehringer Ingelheim)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of NF-kappa-B kinase (IKK) inhibitors
TargetsInhibitor of NF-kappa-B kinase (IKK)
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A